Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. completed the acquisition of Teva Pharma Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V.
August 31, 2024
Share
Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. (TWSE:1795) agreed to acquire Teva Pharma (Thailand) Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. for TWD 1.5 billion on June 6, 2024. As part of the acquisition, Lotus International and Lotus Pharmaceutical acquired 10% and 90% stake respectively in Teva Pharma. A cash consideration of TWD 1.5 billion will be paid by Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. As part of consideration, TWD 1.5 billion is paid towards common equity of Teva Pharma (Thailand) Co., Ltd. The transaction is approved by the board of directors of Lotus Pharmaceutical.
Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. (TWSE:1795) completed the acquisition of Teva Pharma (Thailand) Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. on August 1, 2024.
Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.
Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. completed the acquisition of Teva Pharma Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V.
LOTUS PHARMACEUTICAL CO., LTD. 